FULGENT GENETICS, INC. Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
FULGENT GENETICS, INC. (FLGT) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $62.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-02-27
- FULGENT GENETICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was $41.00K.
- FULGENT GENETICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-12-31 was -$52.00K.
- FULGENT GENETICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-09-30 was -$71.00K.
- FULGENT GENETICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-06-30 was -$291.00K.
- FULGENT GENETICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was $62.00K.
- FULGENT GENETICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was -$994.00K.
- FULGENT GENETICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was -$589.00K.
- FULGENT GENETICS, INC. marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was -$692.00K.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2025-12-31 | $41.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $62.00K 10-K · filed 2026-02-27 | ||
| 2025-09-30 | $21.00K 10-Q · filed 2025-11-07 | |||
| 2024-12-31 | -$52.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$123.00K derived: sum of 2 quarters · filed 2026-02-27 | -$414.00K derived: sum of 3 quarters · filed 2026-02-27 | -$994.00K 10-K · filed 2026-02-27 |
| 2024-09-30 | -$71.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$362.00K derived: sum of 2 quarters · filed 2025-11-07 | -$942.00K 10-Q · filed 2025-11-07 | |
| 2024-06-30 | -$291.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$871.00K 10-Q · filed 2025-08-01 | ||
| 2024-03-31 | -$580.00K 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | -$589.00K 10-K · filed 2026-02-27 | |||
| 2022-12-31 | -$692.00K 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |